1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Suzhou Fengbei Biotech Stock Co.

Suzhou Fengbei Biotech Stock Co.

603334.SS
Suzhou Fengbei Biotech Stock Co.CN flagShanghai Stock Exchange
34.68
CNY
-1.55
- -
1.08BMarket Cap
Suzhou Fengbei Biotech Stock Co.
603334.SS
(Shanghai Stock Exchange)

Recent

price

34.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
27.97
Revenue per Share
- -
- -
- -
- -
- -
1.24
Basic EPS, GAAP
- -
- -
- -
- -
- -
-0.45
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.09
Dividend per Share
- -
- -
- -
- -
- -
6.22
Book Value per Share
- -
- -
- -
- -
- -
14.44
Tangible Book Value per Share
- -
- -
- -
- -
- -
113
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
3,171
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
5.28
Operating Margin (%)
- -
- -
- -
- -
- -
31
Depreciation Expense
- -
- -
- -
- -
- -
141
Net Income, GAAP
- -
- -
- -
- -
- -
8.45
Effective Tax Rate (%)
- -
- -
- -
- -
- -
4.43
Profit Margin (%)
194
- -
- -
- -
- -
1,235
Working Capital
- -
- -
- -
- -
- -
23
LT Debt
- -
- -
- -
- -
- -
1,700
Total Equity
- -
- -
- -
- -
- -
15.78
Return on Invested Capital (%)
- -
- -
- -
- -
- -
30.8
Return on Capital (%)
- -
- -
- -
- -
- -
39.88
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
666
812
919
- -
3,171
2026
1,109
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.34
- -
- -
- -
1.24
2026
0.28
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
0.02
- -
- -
- -
0.09
2026
0.01
- -
- -
- -
- -
Similar Companies
Endonovo Therapeutics, Inc. (ENDV)
Septerna Inc (SEPN)
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Inhibitor Therapeutics, Inc. (INTI)
Brii Biosciences Limited (BRIBF)
Bellerophon Therapeutics, Inc. (BLPH)
Business
Suzhou Fengbei Biotech Stock Co., Ltd. (603334.SS) specializes in the comprehensive utilization of waste oil and fat resources to manufacture and sell resource-based products in China. The company produces bio-based materials serving as additives for pesticides, fertilizers, mineral processing, ink resins, textiles, and biopharmaceuticals; biofuels, primarily biodiesel; oleochemicals including methyl oleate, methylated soybean oil (excluding food products), DD oil, and fatty acids; and industrial packaging materials, with additional involvement in research, development, production, and sales of bio-organic fertilizers, compound microbial fertilizers, bio-pesticide technologies, and fertilizer production services. It operates as an independent import-export agent for commodities and technologies, providing technical services, development, consultation, exchange, transfer, and promotion, primarily from its headquarters at No. 1 Donghai Road, Yangtze River Chemical Industry Park, Zhangjiagang, Jiangsu Province, China, where it was founded in 2014 and employs approximately 360 people. In a major recent development, the company listed its shares on the Main Board of the Shanghai Stock Exchange on November 5, 2025, marking its transition to a publicly traded entity and enhancing its access to capital markets for expansion in the bio-based materials and biofuels sectors.